Why the study?
Does continuous retrograde warm blood reperfusion reduce cardiac troponin I release in patients undergoing heart transplantation?
Does continuous retrograde warm blood reperfusion reduce cardiac troponin I release in patients undergoing heart transplantation?
Continuous retrograde warm blood reperfusion provides better myocardial protection than no reperfusion in heart transplantation when ischemic time exceeds 90 minutes.
Answers are grounded in this paper and cite their sources.
Supports use of continuous retrograde warm cardioplegia for ischemic times >90 min in heart transplantation; extends RCT evidence on myocardial protection.
During heart surgery, cardiac troponin I (cTn-I) measurement provides a tool to evaluate different cardioprotective techniques. To investigate myocardial protection during heart transplantation (HTx), cTn-I and creatine kinase (CK)-MB release was measured in 42 patients randomized to receving either continuous retrograde warm blood reperfusion or no reperfusion after cold cardioplegia. A significant linear correlation was found between donor heart ischemic time and peaks and the area under the curve of cTn-I and CK-MB release. In patients with an ischemic time longer than 90 min, cTn-I release was significantly lower in those receiving continuous retrograde warm cardioplegia than in controls. No significant difference was observed for CK-MB, tCK, and myoglobin. Our data suggest that the measurement of postoperative cTn-I release may provide a method to evaluate ischemic cardiac damage after HTx. When the ischemic time is longer than 90 min, warm retrograde blood cardioplegia provides better myocardial protection than no reperfusion.
No takes yet. Share an insight, caveat, or question.
Fiocchi et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: